Beam Therapeutics reports initial Phase 1/2 data for BEAM — 301 in glycogen storage disease type Ia trial

Beam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type Ia for presentation at ESGCT. Data showed signs of restored patients’ ability to maintain glucose levels following a single dose, with stronger effects at higher dosing. Patients reduced reliance on frequent starch dosing, supporting early clinical proof of concept for mutation-targeted genetic correction. Safety profile looked consistent with lipid nanoparticle therapies, with manageable infusion reactions; no dose-limiting toxicities or deaths were reported. An investor webcast is scheduled for Oct. 27, 2026, ahead of the Oct. 28 poster presentation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610130700PRIMZONEFULLFEED9844240) on October 13, 2026, and is solely responsible for the information contained therein. (C) Copyri